Clinical Trial Update: Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluating azacitidine with or without ATRA in newly diagnosed unfit acute myeloid leukemia or intermediate/high/very high-risk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• ATRA (all-trans retinoic acid)
• AZA (azacitidine)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: AML, MDS | Phase 2, Phase 3 | Status: UNKNOWN